Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma
Scientific Updates June 6,2025
Ming-Chu Chang, Yu-Ting Chang, Jia-Yang Chen, Yung-Ming Jeng , Ching-Yao Yang, Yu-Wen Tien, Shih-Hung Yang, Huai-Lu Chen, Ting-Yuan Liang, Chien-Fang Wang, Eva Y H P Lee, Ying-Chih Chang, Wen-Hwa Lee

Clin Chem. 2016 Mar;62(3):505-13. 

Abstract

Background: Characterization of circulating tumor cells (CTCs) has been used to provide prognostic, predictive, and pharmacodynamic information in many different cancers. However, the clinical significance of CTCs and circulating tumor microemboli (CTM) in patients with pancreatic ductal adenocarcinoma (PDAC) has yet to be determined.

Methods: In this prospective study, CTCs and CTM were enumerated in the peripheral blood of 63 patients with PDAC before treatment using anti-EpCAM (epithelial cell adhesion molecule)-conjugated supported lipid bilayer-coated microfluidic chips. Associations of CTCs and CTM with patients' clinical factors and prognosis were determined.

Results: CTCs were abundant [mean (SD), 70.2 (107.6)] and present in 81% (51 of 63) of patients with PDAC. CTM were present in 81% (51 of 63) of patients with mean (SD) 29.7 (1101.4). CTM was an independent prognostic factor of overall survival (OS) and progression free survival (PFS). Patients were stratified into unfavorable and favorable CTM groups on the basis of CTM more or less than 30 per 2 mL blood, respectively. Patients with baseline unfavorable CTM, compared with patients with favorable CTM, had shorter PFS (2.7 vs 12.1 months; P < 0.0001) and OS (6.4 vs 19.8 months; P < 0.0001). Differences persisted if we stratified patients into early and advanced diseases. The number of CTM before treatment was an independent predictor of PFS and OS after adjustment for clinically significant factors.

Conclusions: The number of CTM, instead of CTCs, before treatment is an independent predictor of PFS and OS in patients with PDAC.

Privacy Preference Center

1. Who We Are
At AcroCyte Therapeutics Inc. (“AcroCyte”, “we”, “our”), we are committed to maintaining the trust and confidence of all visitors to our website, www.acrocyte.com. We value your privacy and want you to be clear about how we handle your data. In particular, AcroCyte is not in the business of selling, renting, or trading email lists with other companies for marketing purposes. This Privacy Policy outlines when and why we collect personal information, how we use it, the limited conditions under which we may disclose it to others, and how we keep it secure.

2. Information We Collect & How We Use It
Contact Forms & Business Inquiries
When you contact us via the forms on our website (such as the "Contact Us" page), we collect the professional information you provide, including your name, email address, phone number, company name, job title, industry, area of interest, and the content of your inquiry.

  • Purpose: We use this data solely to communicate with you, verify your identity, answer your technical or business questions, and provide information about our products and services relevant to your request.
  • Marketing Communications: We will only send you newsletters, product updates, or promotional materials if you have explicitly opted in by checking the relevant box (e.g., "Yes, I'd like to receive updates about AcroCyte news and breakthroughs"). You may unsubscribe from these communications at any time by clicking the "unsubscribe" link in our emails.

Cookies
We use cookies to support essential website functionality and to provide a better user experience. You can choose to disable or delete cookies at any time through your internet browser settings; however, this may limit your ability to use certain features of our website.

3. Third-Party Services & Data Processors

Google Analytics
We use Google Analytics to collect standard internet log information and details of visitor behavior patterns. This helps us understand website traffic and improve performance. This information is processed in a way that does not identify anyone personally. We do not make, and do not allow Google to make, any attempt to find out the identities of those visiting our website.

Google reCAPTCHA
To protect our website forms from spam and automated abuse, we use the reCAPTCHA service provided by Google. This service analyzes behavior to distinguish between humans and bots. Your use of reCAPTCHA is subject to Google’s Privacy Policy and Terms of Service.

Service Providers
We may share your information with trusted third-party service providers who assist us in operating our website, conducting our business, or serving our users (e.g., email delivery services, CRM systems, or hosting providers), so long as those parties agree to keep this information confidential.

4. International Data Transfers
AcroCyte operates globally with offices in Taiwan and the United States. Please be aware that your personal information may be transferred to, stored, and processed in a country other than the one in which you reside. By providing us with your information, you acknowledge and agree to this transfer, storage, or processing. We take all reasonable steps to ensure that your data is treated securely and in accordance with this policy.

5. Data Retention
We retain your personal information only for as long as is necessary to fulfill the purposes for which it was collected, including for the purposes of satisfying any legal, accounting, or reporting requirements. When data is no longer needed, we will securely delete or anonymize it.

6. Access to Your Personal Information & Your Rights
You have the right to request access to, correction of, or deletion of any personal data that we hold about you. Depending on your jurisdiction (such as under the GDPR), you may also have the right to restrict processing, object to processing, or request data portability. To make such a request, please contact our Privacy Team at [info@acrocyte.com].

7. Changes to Our Privacy Policy
We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. The most current version will always be available on our website. By continuing to access or use our website after those changes become effective, you agree to be bound by the revised Privacy Policy.